Skip to main content
. Author manuscript; available in PMC: 2018 Apr 23.
Published in final edited form as: Mol Pharm. 2018 Feb 19;15(3):1062–1072. doi: 10.1021/acs.molpharmaceut.7b00933

Figure 3.

Figure 3

Dose-ranging effects of dsRNA or CpG with alum on vaccine efficacy. Differences in vaccine formulation between the groups are shown below the x-axis. All vaccines in the dsRNA series (Panels A–D) contained 50 μg of Her-TT or KLH (for controls) and glycerol. All vaccines in the CpG series (Panels E–H) contained 50 μg of Her-TT or KLH (for controls) and 50 μg of CpG. Panels A and E are hot plate antinociceptive tests. Panels B and F are tail immersion tests. Panels C and G are antiheroin midpoint titers, and D and H are injection site reactions measured on the day of antinociception. Italicized numbers above the bars represent the ED50 ratio versus nonvaccinated control animals from control A1. A one-way ANOVA was performed for each antinociception assay and the titer data, followed by a Dunnett’s or Tukey’s post hoc comparison test, respectively. *P < 0.05, **P < 0.01, ****P < 0.0001 versus control A1. #P < 0.0001 versus control C1.